Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02137096 · ClinicalTrials.gov registry record · Phase 3

Autologous Stem Cell Transplantation for Patients With Recurrent Nasopharyngeal Carcinoma

A Phase 3 study, sponsored by University of Florida.

Terminated
Registry status
Phase 3
Development phase
1
Enrollment target

NCT02137096 is a Phase 3 study that was terminated before completion, run by University of Florida. The registered enrollment target is 1 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02137096, a Phase 3 study, was terminated before completion, sponsored by University of Florida.

TERMINATED
Registry status
Phase 3
Development phase
1 participants
Enrollment target

Study Summary

This is a pilot study to evaluate the response rates for patients undergoing high dose conditioning chemotherapy using Etoposide, Carboplatin and Ifosfamide followed by autologous stem cell transplantation for the treatment of recurrent Nasopharyngeal Cancer (NPC) in children, adolescents, and young adults.

Interventions

  • DRUG Carboplatin
  • DRUG Ifosfamide
  • DRUG Etoposide phosphate
  • PROCEDURE Autologous Stem Cell Transplantation

Trial Details

FieldValue
Enrollment Target 1 participants
Start Date 2014-06
Est. Completion 2017-05-09
Phase Phase 3

Sponsor

University of Florida

1,106 total trials

What the Registry Record Tells You About NCT02137096

The ClinicalTrials.gov registry entry for NCT02137096 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Florida, which has 1,106 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 4 interventions - of which Carboplatin is the first listed.

NCT02137096 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT02137096 about?

NCT02137096 is a clinical study titled "Autologous Stem Cell Transplantation for Patients With Recurrent Nasopharyngeal Carcinoma". This is a pilot study to evaluate the response rates for patients undergoing high dose conditioning chemotherapy using Etoposide, Carboplatin and Ifosfamide followed by autologous stem cell transplantation for the treatment of recurrent Nasopharyngeal Cancer (NPC) in children, adolescents, and young...

What is the current status of trial NCT02137096?

This trial is currently terminated. It is a Phase 3 study. The enrollment target is 1 participants. The study started on 2014-06. Estimated completion is 2017-05-09.

What interventions are being tested in trial NCT02137096?

The interventions under investigation include: Carboplatin (DRUG), Ifosfamide (DRUG), Etoposide phosphate (DRUG), Autologous Stem Cell Transplantation (PROCEDURE).

Who is sponsoring clinical trial NCT02137096?

This trial is sponsored by University of Florida, which has 1,106 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.